### MINIREVIEWS

4688  Relationship between non-alcoholic fatty liver disease and coronary heart disease  
Arslan U, Yenerçağ M

### ORIGINAL ARTICLE

#### Retrospective Cohort Study

4700  Remission of hepatotoxicity in chronic pulmonary aspergillosis patients after lowering trough concentration of voriconazole  
Teng GJ, Bai XR, Zhang L, Liu HJ, Nie XH

#### Retrospective Study

4708  Endoscopic submucosal dissection as alternative to surgery for complicated gastric heterotopic pancreas  
Noh JH, Kim DH, Kim SW, Park YS, Na HK, Ahn JY, Jung KW, Lee JH, Choi KD, Song HJ, Lee GH, Jung HY

4719  Observation of the effects of three methods for reducing perineal swelling in children with developmental hip dislocation  

4726  Predictive value of serum cystatin C for risk of mortality in severe and critically ill patients with COVID-19  
Li Y, Yang S, Peng D, Zhu HM, Li BY, Yang X, Sun XL, Zhang M

4735  Sleep quality of patients with postoperative glioma at home  
Huang Y, Jiang ZJ, Deng J, Qi YJ

4743  Early complications of preoperative external traction fixation in the staged treatment of tibial fractures: A series of 402 cases  
Yang JZ, Zhu WB, Li LB, Dong QR

4753  Retroperitoneal vs transperitoneal laparoscopic lithotripsy of 20-40 mm renal stones within horseshoe kidneys  

4763  Undifferentiated embryonal sarcoma of the liver: Clinical characteristics and outcomes  
Zhang C, Jia CJ, Xu C, Sheng QJ, Dou XG, Ding Y

4773  Cerebral infarct secondary to traumatic internal carotid artery dissection  
Wang GM, Xue H, Guo ZJ, Yu JL

4785  Home-based nursing for improvement of quality of life and depression in patients with postpartum depression  
Zhuang CY, Lin SY, Cheng CJ, Chen XJ, Shi HL, Sun H, Zhang HY, Fu MA
<table>
<thead>
<tr>
<th>Title</th>
<th>Pages</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observational Study</td>
<td>4793</td>
<td>Palmer J, Leeuwenkamp OR</td>
</tr>
<tr>
<td>Cost-effectiveness of lutetium ($^{177}$Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden</td>
<td></td>
<td></td>
</tr>
<tr>
<td>META-ANALYSIS</td>
<td>4826</td>
<td>Ni DQ, Lu YP, Liu XQ, Gao LY, Huang X</td>
</tr>
<tr>
<td>Underwater vs conventional endoscopic mucosal resection in treatment of colorectal polyps: A meta-analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CASE REPORT</td>
<td>4838</td>
<td>Palladino F, Fedele MC, Casertano M, Liguori L, Esposito T, Guarino S, Miraglia del Giudice E, Marzuillo P</td>
</tr>
<tr>
<td>Dehydrated patient without clinically evident cause: A case report</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intracranial malignant solitary fibrous tumor metastasized to the chest wall: A case report and review of literature</td>
<td>4844</td>
<td>Usuda D, Yamada S, Izumida T, Sangen R, Higashikawa T, Nakagawa K, Iguchi M, Kasamaki Y</td>
</tr>
<tr>
<td>End-of-life home care of an interstitial pneumonia patient supported by high-flow nasal cannula therapy: A case report</td>
<td>4853</td>
<td>Goda K, Kenzaka T, Kuriyama K, Hoshijima M, Akita H</td>
</tr>
<tr>
<td>Rupture of carotid artery pseudoaneurysm in the modern era of definitive chemoradiation for head and neck cancer: Two case reports</td>
<td>4858</td>
<td>Kim M, Hong JH, Park SK, Kim SJ, Lee JH, Byun J, Ko YH</td>
</tr>
<tr>
<td>Paliperidone palmitate-induced facial angioedema: A case report</td>
<td>4876</td>
<td>Srisuengfung M, Sukakul T, Liangcheep C, Viravan N</td>
</tr>
<tr>
<td>Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report</td>
<td>4883</td>
<td>Yang CH, Chen KT, Lin YS, Hsu CY, Ou YC, Tung MC</td>
</tr>
<tr>
<td>Adult metaplastic hutch diverticulum with robotic-assisted diverticulectomy and reconstruction: A case report</td>
<td>4895</td>
<td>Yang CH, Lin YS, Ou YC, Weng WC, Huang LH, Lu CH, Hsu CY, Tung MC</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>4902</td>
<td>Thrombus straddling a patent foramen ovale and pulmonary embolism: A case report</td>
<td>Huang YX, Chen Y, Cao Y, Qiu YG, Zheng JY, Li TC</td>
</tr>
<tr>
<td>4917</td>
<td>Woven coronary artery: A case report</td>
<td>Wei W, Zhang Q, Gao LM</td>
</tr>
<tr>
<td>4922</td>
<td>Idiopathic multicentric Castleman disease with pulmonary and cutaneous lesions treated with tocilizumab: A case report</td>
<td>Han PY, Chi HH, Su YT</td>
</tr>
<tr>
<td>4930</td>
<td>Perianorectal abscesses and fistula due to ingested jujube pit in infant: Two case reports</td>
<td>Liu YH, Lv ZB, Liu JB, Sheng QF</td>
</tr>
<tr>
<td>4946</td>
<td>Systemic autoimmune abnormalities complicated by cytomegalovirus-induced hemophagocytic lymphohistiocytosis: A case report</td>
<td>Miao SX, Wu ZQ, Xu HG</td>
</tr>
<tr>
<td>4953</td>
<td>Nasal mucosa pyoderma vegetans associated with ulcerative colitis: A case report</td>
<td>Yu SX, Cheng XK, Li B, Hao JH</td>
</tr>
<tr>
<td>4958</td>
<td>Amiodarone-induced hepatotoxicity — quantitative measurement of iodine density in the liver using dual-energy computed tomography: Three case reports</td>
<td>Lv HJ, Zhao HW</td>
</tr>
<tr>
<td>4966</td>
<td>Multisystem involvement Langerhans cell histiocytosis in an adult: A case report</td>
<td>Wang BB, Ye JR, Li YL, Jin Y, Chen ZW, Li JM, Li YP</td>
</tr>
<tr>
<td>4981</td>
<td>Catastrophic vertebral artery and subclavian artery pseudoaneurysms caused by a fishbone: A case report</td>
<td>Huang W, Zhang GQ, Wu JJ, Li B, Han SG, Chao M, Jin K</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>5013</td>
<td>Massive gastrointestinal bleeding caused by a Dieulafoy’s lesion in a duodenal diverticulum: A case report</td>
<td>He ZW, Zhong L, Xu H, Shi H, Wang YM, Liu XC</td>
</tr>
<tr>
<td>5019</td>
<td>Plastic bronchitis associated with Botrytis cinerea infection in a child: A case report</td>
<td>Liu YR, Ai T</td>
</tr>
<tr>
<td>5025</td>
<td>Chest, pericardium, abdomen, and thigh penetrating injury by a steel rebar: A case report</td>
<td>Yang XW, Wang WT</td>
</tr>
<tr>
<td>5030</td>
<td>Monocular posterior scleritis presenting as acute conjunctivitis: A case report</td>
<td>Li YZ, Qin XH, Lu JM, Wang YP</td>
</tr>
<tr>
<td>5036</td>
<td>Choriocarcinoma with lumbar muscle metastases: A case report</td>
<td>Pang L, Ma XX</td>
</tr>
<tr>
<td>5042</td>
<td>Primary chondrosarcoma of the liver: A case report</td>
<td>Liu ZY, Jin XM, Yan GH, Jin GY</td>
</tr>
<tr>
<td>5057</td>
<td>Rare imaging findings of hypersensitivity pneumonitis: A case report</td>
<td>Wang HJ, Chen XJ, Fan LX, Qi QL, Chen QZ</td>
</tr>
<tr>
<td>5062</td>
<td>Effective administration of cranial drilling therapy in the treatment of fourth degree temporal, facial and upper limb burns at high altitude: A case report</td>
<td>Shen CM, Li Y, Liu Z, Qi YZ</td>
</tr>
</tbody>
</table>
### ABOUT COVER
Peer-reviewer of *World Journal of Clinical Cases*, Dr. Aleem Ahmed Khan is a Distinguished Scientist and Head of The Central Laboratory for Stem Cell Research and Translational Medicine, Centre for Liver Research and Diagnostics, Deccan College of Medical Sciences, Kanchanbagh, Hyderabad (India). Dr. Aleem completed his Doctorate from Osmania University, Hyderabad in 1998 and has since performed pioneering work in the treatment of acute liver failure and decompensated cirrhosis using hepatic stem cell transplantation. During his extensive research career he supervised 10 PhD students and published > 150 research articles, 7 book chapters, and 2 patents. His ongoing research involves developing innovative technologies for organ regeneration and management of advanced cancers. (L-Editor: Filipodia)

### AIMS AND SCOPE
The primary aim of *World Journal of Clinical Cases (WJCC, World J Clin Cases)* is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

### INDEXING/ABSTRACTING
The WJCC is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, PubMed, and PubMed Central. The 2020 Edition of Journal Citation Reports® cites the 2019 impact factor (IF) for WJCC as 1.013; IF without journal self cites: 0.991; Ranking: 120 among 165 journals in medicine, general and internal; and Quartile category: Q3.

### RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Ji-Hong Liu; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

### NAME OF JOURNAL
*World Journal of Clinical Cases*

### ISSN
ISSN 2307-8960 (online)

### LAUNCH DATE
April 16, 2013

### FREQUENCY
Semimonthly

### EDITORS-IN-CHIEF
Dennis A Bloomfield, Sandro Verto, Bao-Gan Peng

### EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2307-8960/editorialboard.htm

### PUBLICATION DATE
October 26, 2020

### COPYRIGHT
© 2020 Baishideng Publishing Group Inc

### INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

### GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

### GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

### PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

### PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

### ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

### STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/GerInfo/239

### ONLINE SUBMISSION
https://www.iftpublishing.com
Retrospective Study

Predictive value of serum cystatin C for risk of mortality in severe and critically ill patients with COVID-19

Yan Li, Shuang Yang, Ding Peng, Hong-Ming Zhu, Bang-Yi Li, Xiaojiao Yang, Xue-Lian Sun, Mei Zhang

Abstract

BACKGROUND
The outbreak of coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. COVID-19 is clinically categorized into mild, moderate, severe, and critical illness. Acute kidney injury is an independent risk factor for poor prognosis in patients with COVID-19. Serum cystatin C (sCys C) is considered a more sensitive biomarker for early renal insufficiency than conventional indicators of renal function. Early detection of risk factors that affect the prognosis of severe and critically ill patients while using active and effective treatment measures is very important and can effectively reduce the potential mortality rate.

AIM
To determine the predictive value of sCys C for the prognosis of patients with COVID-19.

METHODS
The clinical data of 101 severe and critically ill patients with COVID-19 at a designated hospital in Wuhan, Hubei Province, China were analyzed retrospectively. According to the clinical outcome, the patients were divided into a discharge group (64 cases) and a death group (37 cases). The general information, underlying diseases, and laboratory examination indexes of the two groups were compared. Multivariate Cox regression was used to explore the
because the analysis used anonymous clinical data.

Conflict-of-interest statement: The authors declare no conflict of interest regarding the manuscript.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Received: July 4, 2020
Peered-review started: July 4, 2020
First decision: July 24, 2020
Revised: August 5, 2020
Accepted: September 3, 2020
Article in press: September 3, 2020
Published online: October 26, 2020
P-Reviewer: Yeh YC
S-Editor: Wang JL
L-Editor: Wang TQ
P-Editor: Wang LL

The outbreak of coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. As of June 17, 2020, more than 8 million people have been infected worldwide. The World Health Organization has reported more than 440000 deaths and 130000 new confirmed cases daily. Most patients with COVID-19 have mild symptoms, but approximately 5%-20% have severe symptoms, including acute respiratory distress syndrome, septic shock, and multiple organ failure. The mortality rate of patients with severe COVID-19 was higher than that of patients with mild COVID-19. The later the diagnosis is made, the higher the risk of death.

In addition to the impacts of COVID-19 on the respiratory system and immune system, the kidney is also one of the main organs being affected. Whether COVID-19 patients will develop acute kidney injury (AKI), which may affect their prognosis, is an important issue and worthy of clinical attention. Some studies have shown that AKI is an independent risk factor for poor prognosis in patients with COVID-19[6]. In addition to the direct toxicity of coronaviruses, factors attributed to AKI include systemic hypoxia, coagulation abnormalities, and rhabdomyolysis which may be related to drugs or hyperventilation[7]. Early detection of AKI in patients with COVID-19 is conducive to establishing standardized AKI cluster prevention and treatment (5R principle): Risk screening, early recognition, timely response, renal replacement therapy, and renal recovery, which are key to improve the cure rate and reduce the

relationship between sCys C and prognosis. The receiver operating characteristic (ROC) curve was used to demonstrate the sensitivity and specificity of sCys C and its optimal cut-off value for predicting death.

RESULTS
There were significant differences in age, sCys C, creatinine, C-reactive protein, serum albumin, creatine kinase-MB, alkaline phosphatase, lactate dehydrogenase, neutrophil count, and lymphocyte count between the two groups (P < 0.001). Multivariate logistic regression analysis showed that sCys C was an independent risk factor for death in patients with COVID-19 (Odds ratio = 1.812, 95% confidence interval [CI]: 1.300-2.527, P < 0.001). The area under the ROC curve was 0.755 (95%CI: 1.300-2.527), the cut-off value was 0.80, the specificity was 0.562, and the sensitivity was 0.865.

CONCLUSION
sCys C is an independent risk factor for death in patients with COVID-19. Patients with a sCys C level of 0.80 mg/L or greater are at a high risk of death.

Key Words: COVID-19; Cystatin C; Acute kidney injury; Renal function; Coronavirus infections; Multiple organ dysfunction syndrome

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The novel coronavirus epidemic has become a major public health event in the world. The mortality rate of severe and critical patients is high. It is very important to find an available, cheap, and sensitive biomarker to predict mortality. Cystatin C is a predictor of renal injury. We compared 101 severe and critical patients with coronavirus disease 2019 (COVID-19) in Wuhan, China, and found that patients with a cystatin C level of 0.80 mg/L or greater were at a high risk of death. Therefore, cystatin C may have an important role in the prognosis of severe and critical patients with COVID-19.

URL: https://www.wjgnet.com/2307-8960/full/v8/i20/4726.htm
DOI: https://dx.doi.org/10.12998/wjcc.v8.i20.4726
mortality rate of patients with COVID-19.

Serum cystatin C (sCys C) is a newly developed index with a high sensitivity and specificity for evaluating renal function, which is not affected by age, sex, weight, inflammation, and other factors. It is considered an endogenous marker superior to serum creatinine (sCr){sup 4}. sCys C is a cysteine protease inhibitor, also known as γ-trace basic protein or post-gamma globulin, which is encoded by the Cys C gene that can be continuously transcribed and expressed in all nucleated cells at a constant speed. It has no tissue specificity with a small molecular weight (13 kDa), being positively charged under physiological conditions. It is freely filtered in the glomeruli, completely reabsorbed by the renal tubular epithelial cells, and degraded within cells without returning to the blood. Renal tubular epithelial cells do not secrete sCys C into the lumen, therefore its serum concentration is mainly determined by glomerular filtration rate which is an important indicator of glomerular filtration{sup 5}. In addition, it has been reported that sCys C can be used to evaluate the survival rate of patients with sepsis{sup 6}.

The purpose of this study was to investigate the effect of COVID-19 on renal function and assess the predictive value of sCys C for risk of mortality in critically ill patients with COVID-19.

MATERIALS AND METHODS

Study design and patient population

This single-center retrospective study included adults diagnosed with COVID-19 admitted to the ward of a designated hospital in Wuhan, Hubei Province, from January to March 2020 without any history of chronic kidney disease. The diagnostic criteria were based on the COVID-19 Diagnosis and Treatment Protocol (trial version 7) formulated by the National Health Commission of China, with the epidemiological history and clinical expression of COVID-19, and the etiological or serological evidence (positive novel coronavirus nucleic acid test or serum specific antibody test) considered. Patients recruited in this study were all severe or critically ill patients. Severe condition was determined when subjects had any of the following conditions: (1) Shortness of breath with a respiration rate ≥ 30 times/min; (2) Oxygen saturation ≤ 93% in the resting state; and (3) \( \text{PaO}_2/\text{FiO}_2 \) ≤ 300 mmHg. Subjects were considered critical if any of the following conditions arose: (1) Respiratory failure and need for mechanical ventilation; (2) Shock; and (3) Patients with other organ failure that should be monitored in the intensive care unit (ICU).

This survey was a retrospective study collecting only the clinical data of patients. Since it did not bring risks to patients’ physiology and did not interfere with patients’ treatment plan, and researchers protected patients’ information from disclosure, Xuanwuh Hospital of Capital Medical University agreed to exempt this study from ethical review.

Data collection

All subjects enrolled in our study had a case report form, and data were collected within 12 h after hospital admission, including sex, age, medical history, complications, sCys C, creatine kinase-MB (CK-MB), serum creatinine (sCr), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGTP), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total bilirubin, C-reactive protein (CRP), neutrophil count, albumin, uric acid, lymphocyte count, hemoglobin, platelet count, and blood calcium. All data were obtained from the first laboratory examination after admission. Discharge or death was considered the study outcome.

Statistical analysis

All data were analyzed using SPSS version 22.0. Continuous data (sCr, AST, ALT, etc.) with a normal distribution are presented as the mean ± SD. Non-normally distributed variables are presented as medians with interquartile ranges and analyzed using a non-parametric test. Categorical data (sex, medical history, etc.) were analyzed by the \( \chi^2 \) test. The independent effect of sCys C was calculated using Cox forward stepwise multivariate proportional hazards regression analysis, incorporating classic risk factors. All tests were two-sided, and a \( P \) value of < 0.05 was considered statistically significant. The receiver operating characteristic (ROC) curve was used to demonstrate the sensitivity and specificity of sCys C and its optimal cut-off value for predicting death.
RESULTS

There were a total of 101 cases including 18 critically ill patients and 83 severe patients at baseline, and they were divided into two groups: Discharge group (64 cases) and death group (37 cases). All data were obtained from the first laboratory examination after admission within 12 h after the diagnosis of severe and critical COVID-19. The median length of hospital stay was 15 d. Comparison of the baseline data between the two groups showed that the group of patients who died had the following characteristics: Advanced age (P < 0.001), higher levels of sCys C (P < 0.001), CK-MB (P < 0.001), sCr (P = 0.001), AST (P < 0.001), ALT (P < 0.05), GGTP (P < 0.05), ALP (P < 0.05), LDH (P < 0.001), total bilirubin (P < 0.05), CRP (P < 0.001), and neutrophil count (P < 0.05), and lower levels of albumin (P < 0.001), calcium ion concentration (P < 0.001), lymphocyte count (P < 0.001), and platelet count (P < 0.05) (Table 1).

Predictive value of renal function

By using sCys C, sCr, and the differences in factors as explanatory variables in forward Cox regression analysis to explore the independent factors (Table 2), sCys C was found to be an independent risk factor for death, but the sCr level was not. The ROC curve was used to determine the optimal threshold for predicting the death of severe and critical COVID-19 patients. The results are shown in Figure 1. The area under the curve, optimal threshold, specificity, and sensitivity were 0.755, 0.80, 0.562, and 0.865, respectively. Patients with a sCys C level of 0.80 mg/L or greater were at a high risk of death. The patients were divided into two groups based on a cut-off of 0.80 mg/L, and the survival curve was obtained, as shown in Figure 2. The results demonstrated that this threshold was effective in differentiating high-risk groups (log-rank = 13.375, P < 0.001).

DISCUSSION

From January to March 2020, the clinical data of 101 severe and critically ill patients in a designated hospital in Wuhan, Hubei Province, China were analyzed retrospectively, including 37 dead patients (death group) and 64 surviving patients (discharge group). The risk factors for prognosis were assessed by comparing the laboratory examination results of the discharge and death groups. Multivariate analysis showed that sCys C, CK-MB, AST, albumin, and serum calcium were independent risk factors for death in severe and critically ill patients. The predictive value of CK-MB in patients with COVID-19 has been confirmed by many studies. Wang et al. [7] showed that serum cardiac troponin (cTnI) and CK-MB levels in ICU patients were significantly higher than those in non-ICU patients (P = 0.004), suggesting that increased CK-MB and cTnI levels represent a poor prognosis in patients with COVID-19. Zhou et al. [8] also illustrated that an increase in CK-MB and cTnI levels in COVID-19 patients was significantly correlated with hospital death (P = 0.043). AST and albumin are indicators for liver function, and previous literature supported the predictive value of abnormal liver function in the prognosis of COVID-19 patients. A meta-analysis showed that abnormal liver function indicators such as AST, ALT, bilirubin, and albumin can predict the severity and prognosis of COVID-19 patients [9]. Lei et al. [10] included 5771 adult COVID-19 patients from Hubei Province, and retrospectively analyzed the time distribution of liver function indicators in patients and correlated them with death. The results indicated that abnormal liver function, especially elevated AST, was closely related to the risk of death, which was consistent with the results of this study [10]. In addition, many studies have shown that a decrease in serum calcium is a risk factor for disease severity and death in patients with COVID-19 [11].

Presently, the predictive value of sCys C in the prognosis of patients with COVID-19 is rarely reported, but studies have confirmed that sCys C can predict the risk of AKI and death in critically ill patients such as those with acute cerebral infarction, acute myocardial infarction, heart failure, and sepsis [12,13]. This indicates that sCys C has a predictive value in the prognosis of critically ill patients. However, the predictive value of sCys C for severe and critically ill COVID-19 patients has not been confirmed. In this study, the sCys C level in the death group was significantly higher than that in the discharge group, suggesting that the sCys C level was related to the risk of death in COVID-19. Moreover, multivariate regression analysis showed that the sCys C level was an independent risk factor for the death of patients with COVID-19. To further clarify the correlation between sCys C value and prognosis of COVID-19, we used the ROC curve to assess the cut-off value of sCys C in predicting the death of patients. The
results showed that sCys C had an AUC of 0.755, sensitivity of 0.865, and specificity of 0.562, which indicated that sCys C had appreciated value in predicting the death of patients with severe and critical COVID-19. The cut-off value was 0.80 mg/L, that is, patients with sCys C ≥ 0.80 mg/L are at a high risk of death. The low specificity may be related to the low sample size and retrospective study. Clinicians should be vigilant when patients have sCys C ≥ 0.80 mg/L so that early intervention could be given to improve the prognosis.
Figure 1  Receiver operating characteristic curve of serum cystatin C for predicting the risk of mortality in severe and critically ill patients with coronavirus disease 2019. Area under the curve, optimal threshold, specificity, and sensitivity were 0.755, 0.80, 0.562, and 0.865, respectively.

Figure 2  Effect of serum cystatin C level on patient survival. The Kaplan-Meier survival curves for severe and critically ill coronavirus disease 2019 patients with a cut-off value of serum cystatin C at 0.80 mg/L are shown.

In this study, the sCr level of the dead patients was significantly higher than that of the survivors ($P < 0.01$). However, sCr was not an independent risk factor for death when other different factors were included in the Cox regression equation. Accordingly, sCys C was deemed superior to sCr in predicting the risk of death in severe and critically ill patients with COVID-19. sCys C is a member of the cystatin family. It is freely filtered by the glomerulus, reabsorbed by the proximal tubules, and completely catabolized without returning to the blood stream. Therefore, its...
concentration in the blood is not affected by age, sex, or liver function\[14,15\]. sCys C is generally considered an earlier and more sensitive marker of renal insufficiency than the conventional indicators of renal function such as sCr and blood urea nitrogen (BUN). Numerous studies have shown that there is no significant increase in sCr or BUN levels in the early stage of renal injury, and their elevations can only be observed in the middle and late stages of renal injury. Abnormal levels of indicators usually indicate that renal damage is serious and irreversible\[16\]. Xiang et al\[17\] showed that BUN, sCr, and sCys C (biochemical indicators of renal function) were significantly increased in patients with severe COVID-19, indicating that severe acute respiratory syndrome coronavirus 2 infection may damage the kidney. To date, a number of studies have revealed that patients with COVID-19 may have renal function damage, and the clinical manifestations include rise in sCr, hematuria, albuminuria, and AKI\[18,19\]. It has been reported that the incidence of AKI in patients with COVID-19 ranged from 0.9% to 29%\[20-22\]. For patients who required intensive care, the incidence of AKI increased significantly to 50%\[4\]. Autopsy results indicated that patients with COVID-19 had acute proximal renal tubular injury that was characterized by loss of brush margin, vacuolar degeneration, dilation of the tubular lumen with cell fragments, necrosis, and epithelial exfoliation\[19\]. Pei et al\[23\] showed that the total mortality rate of patients with renal involvement was 11.2%, while the mortality rate of patients without renal involvement was 1.2%, suggesting that renal complications were related to the mortality rate of COVID-19. In addition, another study found that the levels of sCys C were positively correlated with inflammatory reaction indexes such as interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α, and hsCRP, and promoted the occurrence and development of inflammatory reaction. Therefore, in the pathological state of COVID-19 invading lung tissue, sCys C is synthesized and released in large quantities, and the level of sCys C is increased, which regulates the cathepsin activity released from necrotic or inflammatory cells. It is suggested that clinicians should pay close attention to the sCys C level and its changes.

Some limitations pertaining to this study
Since the specificity of the prediction was relatively low, interpretation with caution in clinical practice is suggested. This was a single-center retrospective study and the sample size was relatively small and we lacked clinical data of surviving patients after discharge, thus we were unable to evaluate the effect of sCys C on the long-term prognosis of patients with COVID-19. Our research population was Chinese, further research based on other populations is needed before we can infer the results and draw general conclusions.

CONCLUSION
In conclusion, sCys C can be used as a means for early diagnosis of severe and critical COVID-19 patients with acute renal function damage, providing predictive information for clinical prognosis. Clinicians should improve their understanding pertaining to kidney injury in severe and critically ill patients with COVID-19. Early detection and effective intervention of renal involvement may help reduce potential death in patients with COVID-19.

ARTICLE HIGHLIGHTS

Research background
Coronavirus disease 2019 (COVID-19) is an acute infectious disease caused by a new coronavirus, which is clinically categorized into mild, moderate, severe, and critical illness. Severe and critically ill patients progress rapidly with dyspnea, hypoxemia, and even life-threatening complications such as multiple organ dysfunction syndrome, sepsis, and shock. Early detection of risk factors that affect the prognosis of severe and critically ill patients while using active and effective treatment measures is very important and can effectively reduce the potential mortality rate.

Research motivation
A rapid, effective, and accurate biomarker is urgently needed to predict the prognosis of patients with COVID-19. Serum cystatin C (sCys C) has a predictive value in the prognosis of critically ill patients such as those with acute cerebral infarction, acute
myocardial infarction, heart failure, and sepsis. However, the predictive value of sCys C for severe and critically ill COVID-19 patients has not been confirmed. We designed this study to confirm whether sCys C can be used as a prognostic indicator for COVID-19 patients.

**Research objectives**
The main objective of this study was to determine the predictive value of sCys C for the prognosis of severe and critically ill COVID-19 patients.

**Research methods**
A total of 101 severe or critically ill patients with COVID-19 were divided into a discharge group (64 cases) and a death group (37 cases). We compared the general information, underlying diseases, and laboratory examination indexes of the two groups. Multivariate Cox regression was used to explore the relationship between sCys C and prognosis. In addition, we used the receiver operating characteristic curve to assess the cut-off value of sCys C in predicting the death of patients.

**Research results**
sCys C, creatine kinase-MB, aspartate aminotransferase, albumin, and serum calcium were independent risk factors for death in severe and critically ill patients. sCys C had an AUC of 0.755, sensitivity of 0.865, and specificity of 0.562. Patients with a sCys C level of 0.80 or greater were at a high risk of death.

**Research conclusions**
sCys C is superior to sCr in predicting the risk of death in severe and critically ill patients with COVID-19. Patients with sCys C ≥ 0.80 mg/L are at a high risk of death.

**Research perspectives**
sCys C could be a marker of mortality in severe and critically ill COVID-19 patients.

**REFERENCES**


